PTO/SB/81 (11-04)

Approved for use through 11/30/2005. OMB 0851-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM	Application Number	10/626,794		
	Filing Date	JULY 22, 2003		
	First Named Inventor	TRACEE E.J. EIDENSCHINK		
	Title	BIFURCATION STENT DELIVERY SYSTEM		
	Art Unit	3773		
	Examiner Name	GREGORY A. ANDERSON		
	Attorney Docket Number	1001.2253102		
I hereby revoke all previous powers of attorney given in the above-identified application.				
I hereby appoint:				
Praditioners associated with the Customer Number	28075			
OR				
Practitioner(s) named below:				
Name	Registration Number			

Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to:  $\checkmark$ The address associated with the above-mentioned Customer Number: The address associated with Customer Number ne' Firm or Individual Name Address State City Zip Country

as my/our attempy(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and

l am the Applicant/Inventor. 7

Telephone

Under the Department Deduction Act of 1995, an account are service

Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTC/SB/96)

SATURE of Applicant or Assignee of Record Signature Brown Malin Date SEPTEMBER 4, 2008 Telephone 763, 494, 2425 Name Steven A. McAuley Title and Company Assistant Seed tout Parkat Counsel

Fax

NOTE: Signatures of all the inventors or assigness of recorbof the White Interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below:

\*Total of forms are submitted.

## LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE REGARDING CERTAIN PATENT MATTERS

EFFECTIVE THROUGH: December 31, 2008

I, Lawrence J. Knopf, as Senior Vice President and Deputy General Counsel of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Advanced Stent Technologies, Inc.; AFx, Inc.; AMS Medinvent S.A.; BEI Medical Systems; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); BEI Medical Systems International, Inc.; Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Ireland Limited, Boston Scientific Japan KK; Boston Scientific Limited, Boston Scientific Neuromodulation Corporation; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation, Cardiothoracic Systems, Inc.: Cardiovascular Innovations Canada, Inc.: Catheter Innovations Corp.: Corvita Canada, Inc.: Corvita Corporation: Corvita Europe S.A., CryoVascular Systems, Inc., Embolic Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc., EP Technologies, Inc., Fidus Medical Technology Corporation; Guidant Corporation; Guidant Holdings, Inc.: Guidant Intercontinental Corporation: Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technologies; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Laboratoires Corvita S.A.R.L., Meadox Medicals, Inc., NAMIC Eireann Limited; NAMIC International, Inc., Nilo Holding, S.A.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc., Quanum Corporation; Radio Therapeutics Corporation; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC, Scimed Life Systems, Inc.; Smart Therapeutics, Inc.; Sub-O. Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; TriVascular, Inc.; and Vesica;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation; any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Poissant Reg. No. 56,871	Philip H. LeeReg. No. 50,645
Alana Bergman Reg. No. 47,420	Kurt W. LockwoodReg. No. 40,704
James R. ChiapettaReg. No. 39,634	Jeffrey Z. MannReg. No. 51,994
Richard R. Clapp Reg. No. 31,751	Steven A. McAuleyReg. No. 46,084
Jeffrey P. Cook Reg. No. 48,649	Todd P. MessalReg. No. 42,883
Luke R. Dohmen Reg. No. 36,783	Tyler L. NasiedlakReg. No. 40,099
Peter J. Gafner Reg. No. 36,517	William J. ShawReg. No. 43,111
Lori J. Heinrichs Reg. No. 43,667	Sarah G. StolpmanReg. No. 57,000
Albert K. Kau Reg. No. 40,672	
Lawrence J. Knopf, Senior Vice President and Deputy General Counse	el Date
/ 8	•
COMMONWEALTH OF MASSACHUSETTS ) ) ss.	
COUNTY OF MIDDLESEX )	
On this 9th day of January 2008 before me personally appeared I	awrence J. Knopf to me known and known to me to be the person

Nona & Hurd NOTARY PUBLIC My commission expires Sept 18, 2009

Notary Public

PTO/State (01-49)

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to displays a valid ONE control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner; TRACEE E.J. EIDENSCHINK		
Application No./Patent No.: 10/626,794 Filed/Issue Date: JULY 22, 2003		
Entitled: BIFURCATION STENT DELIVERY SYSTEM		
BOSTON SCIENTIFIC SCIMED, INC. a CORPORATION		
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, uni	versity, government agency, etc.)	
states that it is:		
1. the assignee of the entire right, title, and interest; or		
In an assignee of less than the entire right, title and interest     (The extent (by percentage) of its ownership interest is		
in the patent application/patent identified above by virtue of either:		
A A assignment from the inventor(s) of the patent application/patent identified above. The ass in the United States Patent and Trademark Office at Reel Frame thereof is attached.		
OR B. V A chain of title from the inventor(s), of the patent application/patent identified above, to the co	urrent assignee as follows:	
From: TRACEE E.J. EIDENSCHINK     To: BOSTON SCIENTIFIC SCIMED, INC.     The document was recorded in the United States Patent and Trademark Office at Reel 010588 , Frame 0868 , or for which a copy thereof is attached.		
2. From: SCIMED LIFE SYSTEMS, INCTo: BOSTON SCIENTIFIC SCIMED, INC.		
The document was recorded in the United States Patent and Trademark Office at Reel 010568 , Frame 0868 , or for which a copy thereof is at	tached.	
3. From: To:		
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is a	ittached.	
Additional documents in the chain of title are listed on a supplemental sheet.		
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.		
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO, Seg MPEP 302.06]		
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.		
	EPTEMBER 4, 2008	
Signature	Date	
J. SCOT WICKHEM	612.677.9050	
Printed or Typed Name	Telephone Number	
ATTORNEY FOR APPLICANT(S)		
Title  This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the	a nublic which is to file (and by the	

USPTO to process) an application. Confidentially is government or the process of the process of